RecruitingNot ApplicableNCT05941377

China Antihypertensive Trial for Intracranial Aneurysm (ChATIA-1)

Enhanced Versus Standard Blood Pressure Lowering on Intracranial Aneurysm Rupture or Growth

Sponsor

Beijing Tiantan Hospital

Enrollment

570 participants

Start Date

Jul 1, 2023

Study Type

INTERVENTIONAL

Conditions

Unruptured Intracranial Aneurysm

Summary

The goal of this randomized controlled trial is to evaluate the benefits and safety of controlled hypotension in Chinese patients with unruptured intracranial aneurysms(UIA). The main questions it aims to answer are: * To provide high-level evidence of the benefits and safety of controlled hypotension in patients with UIA. * To provide evidence-based medical evidence for blood pressure control of patients with UIA in neurosurgery, and promote the progress of accurate individual management of patients. In this study, the main intervention is enhanced blood pressure lowering in patients with UIA. All Patients will be randomly assigned to either the standard blood pressure lowering (SBPL) group or the enhanced blood pressure lowering (EBPL) group.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This Chinese trial is studying whether intensive blood pressure lowering can safely prevent the growth or rupture of small, unruptured brain aneurysms (balloon-like bulges in blood vessels in the brain that have not yet burst). **You may be eligible if...** - You are between 18 and 75 years old and of Chinese ethnicity - You have been diagnosed with an unruptured brain aneurysm that is less than 7 mm in size - Your aneurysm has a specific shape and location that makes monitoring appropriate - Your blood pressure is in a range that allows for the treatment being tested **You may NOT be eligible if...** - Your aneurysm is 7 mm or larger - Your aneurysm has already ruptured - Your aneurysm is being treated with surgery or a device (coiling/clipping) - You have uncontrolled high blood pressure or other serious cardiovascular conditions - You have conditions that make intensive blood pressure treatment unsafe Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERblood pressure lowering

For EBPL group, patients are required to keep blood pressure at 100-120 mmHg. For SBPL group, patients are required to keep blood pressure at 120-140 mmHg.